James West
Midas Letter
http://www.midasletter.com/
James West is publisher and editor of The Midas Letter, an independent capital markets entrepreneur and investor. He has spent more than 20 years working as a corporate finance advisor, corporate development officer, investor relations officer, media relations and business development officer for companies involved in mining, oil and gas, alternative fuels, healthcare, Internet technology, transportation, manufacturing and housing construction.
Recent Quotes
"RP recently completed a Phase 1 Clinical Trial that has moved the company that much closer to realizing that goal, and from an investor perspective, the news could not be better."
—
James West, Midas Letter
(3/27/17)
more >
"DXD is a diagnostic technology platform that analyzes changes in telomere structures within DNA to determine aspects and characteristics of deadly diseases like cancer and Alzheimer's Disease."
—
James West, Midas Letter
(9/7/16)
more >
"HLTH delivered stellar Q4/15 and year-end results."
—
James West, Midas Letter
(3/18/16)
more >
"NHC filed its Q3/15 financials, allaying fears of accounting problems."
—
James West, Midas Letter
(1/13/16)
more >
"RP is the first company to ready the technology for its market."
—
The Life Sciences Report Interview with James West
(5/28/14)
more >
"VRS' Aura is a vast improvement over the current technology."
—
The Life Sciences Report Interview with James West
(5/28/14)
more >
"TLT has remarkable early and advanced-stage data coming in for a cancer cure."
—
The Life Sciences Report Interview with James West
(5/28/14)
more >
"BAR's Grasset Nickel project is the hottest play in Canada bar none."
—
James West, Midas Letter
(5/20/14)
more >
